6151-25-3
CAS 6151-25-3
6151-25-3 (CAS 6151-25-3) is a pharmaceutical compound with 3 bioactivity targets and 51 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 13379.197142857143 nM | 35 | - |
| - | AC50 | 13780.191666666666 nM | 6 | - |
| - | IC50 | 30510 nM | 2 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is 6151-25-3 used for in pharmaceutical contexts?
6151-25-3 (CAS 6151-25-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for 6151-25-3?
6151-25-3 has 51 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Allergic sinusitis, Alopecia, Arthritis, COVID-19, Conjunctivitis. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is 6151-25-3 also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Quercetin Dihydrate with EU status "permitted".
What clinical phase is 6151-25-3 in?
No phase 1-4 clinical development badge is rendered for 6151-25-3 because the matched compound identifier rows do not contain a max-phase value.